P3, N=19, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Jun 2026 --> Feb 2027 | Trial primary completion date: Jun 2026 --> Feb 2027

15 hours ago

Trial completion date • Trial primary completion date

HER-2 (Human epidermal growth factor receptor 2) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)

HER-2 positive • PIK3CA mutation

Herceptin (trastuzumab) • Perjeta (pertuzumab) • Piqray (alpelisib)

Adjuvant Aspirin and Cyclooxygenase-2 Inhibitors in Resected, PIK3CA-Mutated Colorectal Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. (PubMed, Crit Rev Oncol Hematol)

Adjuvant NSAID therapy is associated with improved DFS in patients with PIK3CA-mutated CRC. OS benefit remains uncertain, and findings from sensitivity analyses are exploratory. These findings support consideration of NSAIDs as a biomarker-informed adjuvant strategy in selected patients while underscoring the need for confirmatory evidence from ongoing randomized trials.

2 days ago

Retrospective data • Review • Journal

PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)

PIK3CA mutation

aspirin

Prognostic and monitoring value of circulating tumor DNA at multiple clinical time points in breast cancer. (PubMed, Breast Cancer)

ctDNA analysis provides significant clinical utility for prognostic stratification and disease monitoring in breast cancer management.

3 days ago

Journal • Circulating tumor DNA

TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)

TP53 mutation • PIK3CA mutation

A Real-World Study of Precision Treatment for Advanced Cholangiocarcinoma Based on Molecular Subtyping (ChiCTR2500111407)

P=N/A, N=55, Not yet recruiting, Fuzhou University Affiliated Provincial Hospital; Fuzhou University Affiliated Provincial Hospital

3 days ago

New trial

EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MET (MET proto-oncogene, receptor tyrosine kinase) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MSI (Microsatellite instability) • RET (Ret Proto-Oncogene) • FGFR2 (Fibroblast growth factor receptor 2) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • NRG1 (Neuregulin 1) • VEGFA (Vascular endothelial growth factor A) • RNF43 (Ring Finger Protein 43) • TYK2 (Tyrosine Kinase 2) • NTRK (Neurotrophic receptor tyrosine kinase)

BRAF V600E • KRAS mutation • EGFR mutation • MSI-H/dMMR • HER-2 overexpression • HER-2 amplification • PIK3CA mutation • BRAF V600 • MET amplification • RET fusion • FGFR2 mutation • PALB2 mutation • FGFR2 fusion • MET mutation • IDH mutation + BRAF V600E • IDH mutation + NTRK fusion

The safety and efficacy of Osimertinib plus Capivasertib in EGFRm advanced non-small cell lung cancer (NSCLC) participants with PIK3CA/AKT1/PTEN alterations who had progressed on first-line Osimertinib monotherapy or plus chemotherapy: a first-in-human, phase Ib/Ⅱa study (PRECISION) (ChiCTR2600116135)

P1/2, N=47, Not yet recruiting, Cancer Hospital of Shanxi Province; Cancer Hospital of Shanxi Province

3 days ago

New P1/2 trial

PD-L1 (Programmed death ligand 1) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • CD4 (CD4 Molecule)

EGFR mutation • PIK3CA mutation • EGFR L858R • EGFR exon 19 deletion • PTEN mutation • AKT1 mutation

Tagrisso (osimertinib) • Truqap (capivasertib) • simmitinib (SYHA1817)

Liquid biopsy in triple-negative breast cancer: a promising tool for diagnosis, prognosis, and treatment monitoring. (PubMed, Front Oncol)

This review provides a comprehensive overview of the current and future applications of liquid biopsy in TNBC management, highlighting its potential to improve early disease detection, optimize therapeutic strategies, and refine patient classification. Integrating liquid biopsy into routine clinical practice could lead to better treatment outcomes and more personalized approaches to TNBC care.

6 days ago

Review • Journal • Liquid biopsy

TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MIR17 (MicroRNA 17) • MIR105 (MicroRNA 105) • MIR19A (MicroRNA 19a)

TP53 mutation • PIK3CA mutation

Integration of ultrasonography and circulating tumor DNA analysis enhances early detection of asymptomatic ovarian cancer. (PubMed, Ginekol Pol)

Our results suggest that ctDNA is a promising biomarker for the early detection of ovarian cancer, with higher sensitivity and specificity than ultrasound. The combination of ultrasound and ctDNA may provide a more accurate diagnostic strategy for the early detection of ovarian cancer. These findings may contribute to the development of novel noninvasive biomarkers for the early diagnosis of ovarian cancer.

6 days ago

Journal • Circulating tumor DNA

KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)

TP53 mutation • KRAS mutation • PIK3CA mutation

Biomass-Haze PM2.5 from Northern Thailand Drives Genotype-Specific Oxidative Stress and Transcriptomic Remodeling in Non-Small-Cell Lung Cancer Cells. (PubMed, Toxics)

Pathway enrichment analyses highlighted oxidative stress, IL-17, NF-κB, and immune checkpoint signaling. Together, biomass haze-derived PM2.5 from Northern Thailand drives genotype-dependent oxidative stress and transcriptional remodeling in NSCLC cells.

6 days ago

Journal

EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • FAT1 (FAT atypical cadherin 1) • GDF15 (Growth differentiation factor 15) • IL17A (Interleukin 17A) • CYP1A1 (Cytochrome P450 Family 1 Subfamily A Member 1) • CYP1B1 (Cytochrome P450 Family 1 Subfamily B Member 1) • TIPARP (TCDD Inducible Poly(ADP-Ribose) Polymerase)

KRAS mutation • EGFR mutation • PIK3CA mutation

Comprehensive Genomic Characterization of 102 Cervical Adenocarcinoma Tumors. (PubMed, Medicina (Kaunas))

This study validates the primary drivers of cervical adenocarcinoma and reveals novel findings, including notable racial disparities in TP53 mutation frequency and unique patterns of co-occurring mutations. These findings highlight the genomic heterogeneity of the disease and suggest that ancestry and tumor evolution may influence its molecular pathogenesis, offering potential avenues for the development of targeted therapies and personalized biomarkers.

6 days ago

Journal

HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • STK11 (Serine/threonine kinase 11) • ARID1A (AT-rich interaction domain 1A) • BCL6 (B-cell CLL/lymphoma 6) • MSH2 (MutS Homolog 2)

TP53 mutation • KRAS mutation • HER-2 amplification • PIK3CA mutation • ATM mutation • ARID1A mutation • STK11 mutation

Molecular Landscape of Advanced Endometrial Cancer: Exploratory Analyses at Modena Cancer Center (MEMO). (PubMed, Int J Mol Sci)

Our findings underscore the need for further investigation into the molecular landscape of advanced endometrial cancer, particularly in the context of therapeutic implications. Combinatorial treatment strategies targeting specific molecular alterations, such as KRAS, in combination with other targeted agents or therapeutic approaches, warrant further exploration.

6 days ago

Journal

KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • PPP2R1A (Protein Phosphatase 2 Scaffold Subunit Aalpha)

TP53 mutation • KRAS mutation • PIK3CA mutation • PTEN mutation

Association of TIGIT and CD155 with KRAS, NRAS, BRAF, PIK3CA, and AKT Gene Mutations, MSI Status, and Cytokine Profiles in Colorectal Cancer. (PubMed, Int J Mol Sci)

In external transcriptomic validation (TCGA-CRC), GSEA indicated enrichment of interferon/inflammatory programs in TIGIT-high tumors, while CD155-high tumors preferentially showed proliferation-related MYC/E2F/G2M signatures. Together, these findings support tumor-wide upregulation of the TIGIT/CD155 axis in CRC and suggest that TIGIT, more than CD155, tracks with MSI/BRAF-associated immune activation, providing a rationale for patient stratification in checkpoint-directed immunotherapy.

6 days ago

Journal • IO biomarker

KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • NRAS (Neuroblastoma RAS viral oncogene homolog) • MSI (Microsatellite instability) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • IFNG (Interferon, gamma) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CSF1 (Colony stimulating factor 1) • PVR (PVR Cell Adhesion Molecule) • IL1R1 (Interleukin 1 receptor, type I)

BRAF mutation • PIK3CA mutation • BRAF wild-type • AKT1 mutation

GenBlosum: On Determining Whether Cancer Mutations Are Functional or Random. (PubMed, Genes (Basel))

Codon-aware neutral modeling provides a statistical framework for distinguishing mutations that deviate from stochastic expectations and may aid in the interpretation of variants of unspecified significance. By contextualizing mutational severity relative to neutral processes, this approach offers insight into tumor evolution and may support prognostic assessment without relying on predefined gene-level neutrality.

6 days ago

Journal • BRCA Biomarker

TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • BRCA (Breast cancer early onset)

TP53 mutation • PIK3CA mutation • BRCA mutation